The North America autoimmune disease diagnostics market is expected to register a CAGR of 7.8% during the forecast period of 2018–2023. The key factors propelling the market include growing public awareness about autoimmune disease, improving laboratory automation, partnerships with physicians and clinical laboratories, technological advancements, expansion in coverage allowed by the Patient Protection and Affordable Care Act.
The rising awareness about autoimmune diseases through programs of research, education, support, and advocacy is a key factor boosting the usage rates. It is imperative that the public is more aware of their own risk factors for developing auto-immune diseases so that, as symptoms occur, they can seek diagnosis, and begin a treatment regimen. The United States has the highest incidence of autoimmune diseases where, about 50 million patients suffer from autoimmune diseases. The American Autoimmune Related Diseases Association (AARDA) aims to increase awareness about the socioeconomic impact of autoimmunity through fostering and facilitating collaboration in the areas of education, public awareness, research, and patient services in an effective, ethical, and efficient manner. Similarly, there are other organizations who are striving to improve the R&D funding, patient awareness, and provide other socio-economic benefits to the patients. Moreover, the increase in awareness levels coupled with improving healthcare infrastructure and reimbursement coverage is expected to drive the market over the forecast period. The other factors, such as improved laboratory automation, partnerships with physicians and clinical laboratories, technological advancements and expansion in coverage allowed by the Patient Protection and Affordable Care Act are driving the North American autoimmune disease diagnostics market.
Diagnosis of auto-immune diseases is a time-consuming process. It involves procedures such as serum testing for diseases like rheumatoid arthritis, Addison’s disease, Hashimoto’s disease, and others. Testing protocols allow autoimmune disorders to be diagnosed in a highly efficient, cost-effective manner. However, the turnaround time for the test results is slow, owing to lesser automation techniques. It takes days to deliver all test results to the patients with proper explanation of false positive results. For example autoimmune lymph proliferative syndrome is an autoimmune disease with a turnaround time of up to 12 weeks. A single gene sequencing takes four weeks.Therefore, this slow turnaround time is hindering the North American autoimmune disease diagnostics market. The other factor such as the high frequency of false positive result is also hindering the growth of the market.
The United States autoimmune disease diagnostics market held the largest market share, in 2017, in North America due to the increasing healthcare expenditure and increasing prevalence of autoimmune diseases in this region. In the United States, 16% of the population suffers from autoimmune diseases, 78% of whom are women.
The major players include F. Hoffmann-la Roche, Euroimmun AG, Inova Diagnostics Inc., Siemens HealthineersInc, Biomérieux, Trinity Biotech, Thermo Fisher Scientific, Myriad Genetics, Abbott Laboratories, and Bio-rad Laboratories, among others.
Looking to Customize Report?